InteRNA Technologies
Business Services · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Jonkerbosplein Nijmegen City Centre 52, ...Phone Number
+31 302532386Website
www.interna-technologies.comRevenue
$5.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About InteRNA Technologies
InteRNA Technologies, found in and based in Nijmegen, Netherlands, is a clinical-stage biotech company developing a pipeline of proprietary microRNA (miRNA) therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer.Explore more
InteRNA Technologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is InteRNA Technologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
InteRNA Technologies, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if InteRNA Technologies is spiking on competitors!
Earning: See what the market has to say on InteRNA Technologies recently announced quarterly report
Funding: Get notified immidiatlly once InteRNA Technologies has new funding data
Congratulate Masked Content for being promoted to Masked Content at InteRNA Technologies
Product Launch: Get notified when InteRNA Technologies launches new products
Click to see if InteRNA Technologies had a recent Job posting/layoffs
Check if InteRNA Technologies has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at InteRNA Technologies
Find 3 more new buyers
Company Profile Activity
Activity Insights
InteRNA Technologies is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
InteRNA Technologies is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about InteRNA Technologies.
InteRNA Technologies financials insights
Gather financial insights about InteRNA Technologies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$10.5M
2021
Series B
$22.4M
InteRNA Technologies Tech Stack
A closer look at the technologies used by InteRNA Technologies
InteRNA Technologies News & Media
InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board
UTRECHT, The Netherlands--(BUSINESS WIRE)--InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, today announced the establishment of a Clinical Advisory Board (CAB) and the appointment of new members to its Scientific Advisory Board (SAB). Both the SAB and CAB will further guide the Company in the development of cancer therapies that are based on the unique features of InteRNA’s proprietary miRNAs. The CAB is chaired by EmInteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board
UTRECHT, The Netherlands--(BUSINESS WIRE)--InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today the appointment of Andrea van Elsas, PhD, as a new member of the Company’s Supervisory Board. Dr. van Elsas transitions from the Company’s Scientific Advisory Board where he served as a member since February 2019. He will succeed Mark Vaeck, PhD, who has stepped down from his position on the Supervisory Board. “AInteRNA Technologies Publishes Preclinical Data from Investigational microRNA INT-1B3 Program in Molecular Therapy – Nucleic Acids and Oncotarget
UTRECHT, The Netherlands--(BUSINESS WIRE)--InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, today announced that preclinical data investigating the Company’s lead candidate, INT-1B3, have been published in the peer-reviewed journals Molecular Therapy – Nucleic Acids and Oncotarget. INT-1B3 is a mimic of the tumor suppressor miRNA-193a-3p and has the potential to address multiple hallmarks of cancer at the same time. ThInteRNA Technologies Awarded € 2.7M Clinical Innovation Credit from Dutch Government
UTRECHT, The Netherlands--(BUSINESS WIRE)--InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, today announced that it was awarded a Clinical Innovation Credit of € 2.7 Million from the Dutch government. This award will support the clinical validation of the Company’s lead candidate, INT-1B3, for the treatment of solid tumors. The funding is granted by the ‘Rijksdienst voor Ondernemend Nederland’/The Netherlands Enterpris
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding InteRNA Technologies
Sign Up For FreeTo access detailed company insights
InteRNA Technologies, found in and based in Nijmegen, Netherlands, is a clinical-stage biotech company developing a pipeline of proprietary microRNA (miRNA) therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer.... Read More
